AstraZeneca's $15.6B acquisition of MedImmune will prove to be stragically wise, providing a much needed boost to the company's pipeline in the long term.
AstraZeneca has a highly profitable portfolio of core medicines that is young and well diversified. These medicines will continue to produce strong cash flow and earnings in the short to mid-term.